FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition
Executive Summary
Patents that claim any unapproved aspects of an approved drug should not be listed in the "Orange Book," the Federal Trade Commission maintained.
You may also be interested in...
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
FDA Waxman/Hatch Fix Proposal Is “Beefed-Up” Patent Declarations
FDA is considering requiring innovator companies to provide more information about patents they file for listing in the "Orange Book" as one remedy to Waxman/Hatch loopholes